The aim of the NeoPower study was to collect and analyze the data of patients with HER2 + early breast cancer (eBC) treated in the neoadjuvant setting with P, H and chemotherapy in different cancer centers in Emilia Romagna, in order to evaluate the tolerability and efficacy of the treatment in real life. This evidence concerns the gene ERBB2 and breast carcinoma.